Stock Analysis on Net

CVS Health Corp. (NYSE:CVS)

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

CVS Health Corp., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Products 65,154 61,298 60,539 58,147 59,657 57,643 56,794 52,522 53,973 51,853 50,525 47,387 49,592 47,738 46,355 47,003 49,213 47,149 45,531 43,343
Premiums 25,075 24,657 25,108 24,352 21,436 21,003 21,260 21,631 19,205 18,984 18,983 18,960 17,615 17,182 16,927 17,640 15,510 15,539 15,791 16,282
Services 3,316 3,532 3,000 2,445 2,430 2,312 2,436 2,505 3,059 2,711 2,819 2,453 2,099 1,932 1,875 1,950 1,960 1,859 1,816 1,772
Revenues from customers 93,545 89,487 88,647 84,944 83,523 80,958 80,490 76,658 76,237 73,548 72,327 68,800 69,306 66,852 65,157 66,593 66,683 64,547 63,138 61,397
Cost of products sold (57,419) (54,688) (53,536) (51,455) (51,728) (50,365) (49,290) (45,509) (46,378) (45,011) (43,520) (40,894) (42,452) (40,940) (40,242) (40,347) (42,065) (40,437) (38,970) (37,247)
Health care costs (22,518) (21,499) (21,782) (20,448) (18,305) (17,419) (17,606) (17,951) (16,574) (16,081) (15,901) (15,704) (15,145) (14,396) (11,751) (14,387) (13,133) (12,850) (13,087) (13,459)
Cost of revenues (79,937) (76,187) (75,318) (71,903) (70,033) (67,784) (66,896) (63,460) (62,952) (61,092) (59,421) (56,598) (57,597) (55,336) (51,993) (54,734) (55,198) (53,287) (52,057) (50,706)
Gross profit 13,608 13,300 13,329 13,041 13,490 13,174 13,594 13,198 13,285 12,456 12,906 12,202 11,709 11,516 13,164 11,859 11,485 11,260 11,081 10,691
Net investment income 268 277 274 334 323 201 146 168 367 246 289 297 248 204 184 162 206 263 293 249
Restructuring charges (11) (496)
Opioid litigation charges (583) (5,220)
Loss on assets held for sale (349) (53) (2,480)
Store impairments (1,358)
Goodwill impairment (431)
Operating expenses (10,503) (9,876) (9,873) (9,580) (9,559) (9,606) (9,171) (9,876) (10,065) (9,210) (8,869) (8,922) (9,433) (8,471) (8,668) (8,563) (8,654) (8,595) (8,042) (8,250)
Operating income (loss) 3,373 3,690 3,234 3,446 3,618 (3,931) 4,569 3,490 2,229 3,061 4,326 3,577 2,524 3,249 4,680 3,458 3,037 2,928 3,332 2,690
Interest expense (690) (693) (686) (589) (552) (566) (583) (586) (608) (602) (636) (657) (678) (731) (765) (733) (734) (747) (772) (782)
Loss on early extinguishment of debt (89) (363) (674) (766) (79)
Other income 22 22 22 22 43 41 43 42 38 49 45 50 53 54 45 54 31 31 31 31
Income (loss) before income tax (provision) benefit 2,705 3,019 2,570 2,879 3,109 (4,456) 4,029 2,946 1,570 2,145 3,735 2,970 1,225 1,806 3,960 2,779 2,334 2,133 2,591 1,939
Income tax (provision) benefit (658) (754) (656) (737) (809) 1,047 (1,068) (633) (274) (558) (944) (746) (241) (587) (974) (767) (590) (604) (660) (512)
Income (loss) from continuing operations 2,047 2,265 1,914 2,142 2,300 (3,409) 2,961 2,313 1,296 1,587 2,791 2,224 984 1,219 2,986 2,012 1,744 1,529 1,931 1,427
Loss from discontinued operations, net of tax (9)
Net income (loss) 2,047 2,265 1,914 2,142 2,300 (3,409) 2,961 2,313 1,296 1,587 2,791 2,224 975 1,219 2,986 2,012 1,744 1,529 1,931 1,427
Net (income) loss attributable to noncontrolling interests (1) (4) (13) (6) 2 (7) (10) (1) 10 11 (8) (1) (2) 5 (11) (5) 3 1 5 (6)
Net income (loss) attributable to CVS Health 2,046 2,261 1,901 2,136 2,302 (3,416) 2,951 2,312 1,306 1,598 2,783 2,223 973 1,224 2,975 2,007 1,747 1,530 1,936 1,421

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Revenues from customers Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. CVS Health Corp. revenues from customers increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. CVS Health Corp. operating income (loss) increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Income (loss) before income tax (provision) benefit Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. CVS Health Corp. income (loss) before income tax (provision) benefit increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Net income (loss) attributable to CVS Health The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. CVS Health Corp. net income (loss) attributable to CVS Health increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.